NCT01358721 - Phase I Biomarker Study (BMS-936558) | Biotech Hunter

Enrollment

119

Participants

Timeline

Start Date

September 23, 2011

Primary Completion Date

December 1, 2014

Study Completion Date

May 22, 2019

Conditions

Renal Cell Carcinoma

Interventions

DRUG

BMS-936558 (Anti-PD-1)

Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response

DRUG

BMS-936558 (Anti-PD-1)

Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response

DRUG

BMS-936558 (Anti-PD-1)

Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response

Trial Locations (14)

15232

Upmc Cancer Pavilion, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

21231

The Bunting-Blaustein Cancer Research Building, Baltimore

27710

Duke University Medical Center, Durham

31192

Local Institution, Pamplona

33612

H. Lee Moffitt Cancer Center, Tampa

53705

University Of Wisconsin Carbone Cancer Center, Madison

60637

University Of Chicago Medical Center, Chicago

94115

Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco

94805

Local Institution, Villejuif

97213

Providence Portland Med Ctr, Portland

06520

Yale University School Of Medicine, New Haven

02215

Dana Farber Cancer Institute, Boston

Dana Farber Cancer Inst, Boston